Regeneron Pharmaceuticals, Inc.

-7.07 (-1.14%)
Regulatory, Other Pre-Announcement

Regeneron Announces Topline Phase 2 Data Of High-Dose Aflibercept In Wet Age-Related Macular Degeneration

Published: 08/24/2021 11:46 GMT
Regeneron Pharmaceuticals, Inc. (REGN) - Regeneron Announces Encouraging Topline Phase 2 Data of High-dose Aflibercept in Wet Age-related Macular Degeneration.
Regeneron Pharmaceuticals Inc - Phase 3 Trials in Wet Amd and Diabetic Macular Edema Fully Recruited, With Results Expected in Second Half of 2022.
Regeneron - Ongoing Phase 2 Proof-of-concept Trial Evaluating an Investigational 8 Mg Dose of Aflibercept Met Its Primary Safety Endpoint.
Regeneron Pharmaceuticals Inc - No New Safety Signals Observed Compared to Currently-approved 2 Mg Dose of Eylea(®) (aflibercept) Injection in Patients.